Last updated on April 2018

Do you have Metastatic Pancreatic Adenocarcinoma?


Brief description of study

To compare overall survival (OS) of patients with metastatic pancreatic adenocarcinoma (PDAC) treated with BBI-608 plus weekly nab-paclitaxel with gemcitabine (Arm 1) versus weekly nab-paclitaxel with gemcitabine (Arm 2).

Clinical Study Identifier: TX155591

Contact Investigators or Research Sites near you

Start Over